The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Across all products, Biogen's sales declined 7% to ... But that still topped calls for $430 million, according to FactSet. Overall, Biogen's MS drugs brought in $1.08 billion in sales, narrowly ...

Communications agency Pegasus was given a brief to create an engaging platform capable of improving the understanding of MS and one of Biogen’s products among MS professionals. The result was MS ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Amid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the ...

Biogen, Inc. is a biopharmaceutical ... diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA ...

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue ...

Biogen is in a difficult balancing act “with ... Piper Sandler flagged several headwinds for MS products, including competition from biosimilars and upcoming loss of exclusivity for key drugs ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international litigation with mixed rulings | Generics still barred from selling products ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other NASDAQ 100 stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK ... the Committee for Medicinal Products for Human Use (CHMP), an expert panel of the European Medicines Agency, recommended lecanemab for a narrower group ...